Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Accured Expenses (2016 - 2026)

Aytu Biopharma has reported Change in Accured Expenses over the past 15 years, most recently at $3.5 million for Q4 2025.

  • Quarterly Change in Accured Expenses fell 52.72% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $364000.0 through Dec 2025, up 111.15% year-over-year, with the annual reading at $886000.0 for FY2025, 109.67% up from the prior year.
  • Change in Accured Expenses was $3.5 million for Q4 2025 at Aytu Biopharma, up from -$1.6 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $8.0 million in Q1 2023 and troughed at -$14.5 million in Q2 2022.
  • The 5-year median for Change in Accured Expenses is $164000.0 (2024), against an average of -$706210.5.
  • Year-over-year, Change in Accured Expenses crashed 574.67% in 2022 and then soared 879.88% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$3.9 million in 2021, then soared by 162.73% to $2.5 million in 2022, then crashed by 48.52% to $1.3 million in 2023, then surged by 474.23% to $7.3 million in 2024, then plummeted by 52.72% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Change in Accured Expenses are $3.5 million (Q4 2025), -$1.6 million (Q3 2025), and -$3.1 million (Q2 2025).